Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Ikena Oncology (Nasdaq: IKNA) will participate in the Targeted Oncology Panel at the Cowen & Co 42nd Annual Health Care Conference scheduled for March 7-9, 2022.

CEO Mark Manfredi will speak on March 8 at 9:10 a.m. ET.

The event will be streamed live and archived for 30 days. Ikena focuses on developing therapies targeting cancer pathways, with its lead program IK-930 being a TEAD inhibitor for the Hippo pathway, among others.

For more details, visit www.ikenaoncology.com.

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that management will be participating in the Targeted Oncology Panel at the Cowen & Co 42^nd Annual Health Care Conference, taking place March 7-9, 2022. The Company will also be holding investor meetings at the conference.

Details on the panel can be found below:

Mark Manfredi, PhD, Chief Executive Officer
Date: March 8, 2022
Time: 9:10 a.m. ET
Webcast Link: Targeted Oncology Panel

The webcast link will stream the live panel and will be archived for 30 days following the end of the conference, accessible above. The presentation webcast can also be accessed by visiting the Investors & Media section of the company’s website at www.ikenaoncology.com.

About Ikena Oncology
Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. The Company’s lead targeted oncology program, IK-930, is a TEAD inhibitor addressing the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. Additional programs include an ERK5 inhibitor program targeting the RAS signaling pathway and programs targeting the tumor microenvironment and immune signals, two of which are being developed in collaboration with Bristol Myers Squibb, including IK-175, an aryl hydrocarbon receptor antagonist designed to modulate the tumor microenvironment. Ikena’s pipeline is built on addressing genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.

Media Contact:
Gwen Schanker
LifeSci Communications
gschanker@lifescicomms.com


Investor Contact:
Rebecca Cohen
Ikena Oncology
rcohen@ikenaoncology.com

FAQ

What is Ikena Oncology's participation in the Cowen & Co Health Care Conference 2022?

Ikena Oncology will participate in the Targeted Oncology Panel at the Cowen & Co 42nd Annual Health Care Conference from March 7-9, 2022.

When will Ikena Oncology CEO Mark Manfredi speak at the conference?

Mark Manfredi, CEO of Ikena Oncology, will speak on March 8, 2022, at 9:10 a.m. ET.

How can I watch the Ikena Oncology panel at the Cowen & Co conference?

The panel will be streamed live and archived for 30 days. You can access it through the webcast link provided in the press release.

What is the main focus of Ikena Oncology's research?

Ikena Oncology focuses on developing therapies targeting signaling pathways that drive cancer formation and spread, including its lead program IK-930.

Where can I find more information about Ikena Oncology?

More information about Ikena Oncology can be found on their official website at www.ikenaoncology.com.